BrightSpring Health Services(BTSG) - 2024 Q2 - Earnings Call Presentation

Financial Performance - Q2 2024 - BrightSpring's total revenue for Q2 2024 was $2730 million, a 260% increase year-over-year[5,6] - Pharmacy Solutions revenue reached $2114 million, representing a 324% year-over-year growth[5,6,9] - Infusion and Specialty Pharmacy revenue was $1586 million, a 403% increase year-over-year[5,7] - Home and Community Pharmacy revenue amounted to $528 million, showing a 133% year-over-year increase[5,7] - Provider Services revenue was $616 million, an 80% increase year-over-year[5,6,9] - Adjusted EBITDA for Q2 2024 was $1391 million, a 167% increase year-over-year, excluding a $30 million Quality Incentive Payment (QIP) in Q2 2023[5,6] - Pharmacy Solutions segment EBITDA was $94 million, an 187% increase year-over-year, excluding the QIP[5,7,9] - Provider Services segment EBITDA was $86 million, a 157% increase year-over-year[5,8,9] Key Business Metrics - Pharmacy Solutions dispensed 10120 thousand prescriptions in Q2 2024, a 91% increase year-over-year[7] - Pharmacy Solutions revenue per script was $20894 in Q2 2024, a 237% increase year-over-year[7] - Home Health Care average daily census was 44246 in Q2 2024, a 132% increase year-over-year[8] Fiscal Year 2024 Guidance (Updated August 2024) - Total revenue is projected to be between $10450 million and $10900 million, representing an 184% to 235% year-over-year increase[10] - Pharmacy revenue is projected to be between $8000 million and $8400 million, representing a 227% to 288% year-over-year increase[10] - Provider revenue is projected to be between $2450 million and $2500 million, representing a 63% to 85% year-over-year increase[10] - Adjusted EBITDA is projected to be between $570 million and $580 million, representing a 60% to 78% year-over-year increase[10]